Lekha Mikkilineni, M.D.
Dr. Mikkilineni treats patients with hematological malignancies (multiple myeloma, lymphoma and leukemia) with chimeric antigen receptor (CAR) T-cell therapy. Her research focuses on bringing novel multiple myeloma CAR T-cell therapies to patients through phase 1 clinical trials at the NIH Clinical Center. She is interested in patient outcomes with cellular therapies as well as understanding and managing the side effects associated with cellular therapy and immunotherapy.
1) multiple myeloma, 2) chimeric antigen receptor (CAR) T-cell therapy, 3) blood cancer (including Hodgkin and non-Hodgkin lymphoma), 4) immunotherapy
Dr. Mikkilineni conducts clinical trials to investigate new therapies for hematologic malignancies. She focuses on developing and running phase 1 clinical trials testing chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.
Selected Key Publications
- Blood. 130(24): 2594-2602, 2017. [ Journal Article ]
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.J Clin Oncol. 6(22): 2267-2280, 2018. [ Journal Article ]
Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment.Semin Oncol. 44(3): 218-225, 2017. [ Journal Article ]
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.Nat Med. 26(2): 270-280, 2020. [ Journal Article ]
Dr. Mikkilineni received a Bachelor of Arts and Bachelor of Science from the University of California, San Diego, and a Masters of Art from Boston University. She received her M.D. from the Tulane University School of Medicine and completed her internship and internal medicine residency training at Thomas Jefferson University and Hospitals. She then completed fellowship training in medical oncology and hematology through a joint program sponsored by the National Cancer Institute and the National Heart, Lung and Blood Institute. During this fellowship she joined Dr. Kochenderfer’s research group and began to focus on bringing novel CAR T-cell therapies from the lab to phase 1 clinical trials. As a result of her work, she received the ASCO Conquer Cancer Foundation Young Investigator Award in 2019. Dr. Mikkilineni was selected as a Society for Immunotherapy of Cancer Fellow before joining as full-time faculty with the research group of Dr. James Kochenderfer in the Surgery Branch.